11/06/2026
In a recent interview, our CEO Ian Crosbie discusses the alfapump System, the patients we serve, and what it means to be in the U.S. market delivering a modern treatment option for those living with recurrent or refractory ascites due to liver cirrhosis.
From the pivotal POSEIDON study to FDA approval and commercial launch, Ian shares the milestones that have shaped Sequana Medical and the vision for making the alfapump the new standard of care.
Read the full interview: https://pulse2.com/sequana-medical-profile-ian-crosbie-interview/
For important safety information, visit:https://www.sequanamedical.com/wp-content/uploads/ISI.pdf